VYEPTI AAN 2026 INFUSE — Migraine Cognitive Symptoms Visualization. Women 3x Chronic Pain New Dimension
Migraine 3x more common in women than men. Hormonal·pregnancy·menopause influenced. Previous treatments measured only headache frequency. Lundbeck 2026.4.20 AAN 2026 — VYEPTI (eptinezumab) INFUSE real-world 6-month data visualizes headache frequency + brain fog·concentration cognitive symptoms.
Key Announcement
VYEPTI: anti-CGRP monoclonal antibody (Lundbeck), 30+ countries launch, IV quarterly infusion, chronic·episodic migraine prevention
INFUSE Real-World Study (AAN 2026): Presented 2026.4.20, post-1+ anti-CGRP failure, 6-month real-world, headache frequency + cognitive symptoms measured
New Measurement - Cognitive Symptoms
Existing: MMD (monthly migraine days), MHD, pain intensity (NRS)
INFUSE additional: Brain fog, attention, memory, processing speed
Migraine - Women’s Blind Spot
Prevalence: Women 18~25%, men 6~8%, women:men 3:1, 25~55 years common
Women-specific (hormones): Post-puberty ↑, menstrual migraine (PMS-linked), pregnancy 60~70% improvement, postpartum recurrence, perimenopause worsening, post-menopause partial stabilization
Cognitive burden: Work·housework·childcare impact, work absence·productivity ↓, Korea ~2M+ women migraine patients
anti-CGRP Drugs
Existing: VYEPTI IV quarterly (L74), Aimovig (erenumab), Ajovy, Emgality, Nurtec (oral)
VYEPTI differentiation: IV quarterly (vs SQ monthly), 100% bioavailability, quarterly convenience, clinician monitoring, fast onset
L74 Expansion·Global·Policy Dimension - 1st Axis
40 pillars + chronic pain new area: L66 Auvelity·L70 SAINT TMS (depression) + L71 Centanafadine (ADHD) + L74 VYEPTI INFUSE (migraine cognitive) = women’s chronic pain first visualization entry.
Korean Implications
VYEPTI Korean MFDS approved (2024), insurance (chronic migraine), 100~200K KRW/quarterly. INFUSE significance: cognitive burden measurement standardization, patient effect precision, work·daily impact quantification.
Daily Guide - Women’s Migraine
Tracking: Headache diary (app·paper), triggers (food·sleep·stress·hormones), drug response
Hormone management: Pre/post-menstrual prophylaxis, pregnancy planning drug adjustment, perimenopause doctor consult
Daily prevention: Regular sleep (79 hours), consistent caffeine, exercise (aerobic 34x/week), meditation·CBT
Drug stages: 1st NSAID·triptan (acute), prevention beta-blocker·antidepressant·anticonvulsant, anti-CGRP (VYEPTI·Aimovig·Ajovy·Emgality)
FAQ
Q. Migraine = simple headache? A. Neurological disease. Headache + nausea·photophobia·sound sensitivity·cognitive impairment. Big daily impact.
Q. VYEPTI effective fast? A. IV quarterly = hours-onset. Faster than SQ. But clinician infusion needed.
Q. Brain fog really improves with drug? A. INFUSE real-world data = measurable improvement. Patient variability. Doctor evaluation.
Q. Post-menopause migraine stabilizes? A. Partial. But hormone fluctuation·existing triggers continue. Drug + hormone consult.
Conclusion
VYEPTI AAN 2026 INFUSE = migraine cognitive symptoms visualization global data. Women 3x chronic pain new dimension. L74 = 55 pillars + expansion·global·policy dimension (pain new area 1st axis). Global 30 countries real-world. Cognitive burden measurement = daily·work impact quantified.